Financial Performance - In 2019, the company achieved a net profit of CNY 23,186,862.24, with a 10% statutory reserve fund of CNY 2,318,686.22, resulting in a distributable profit of CNY 20,868,176.02 for shareholders[4]. - The total revenue for 2019 was CNY 754,544,013.66, representing a 1.26% increase from CNY 745,161,287.68 in 2018[19]. - The net profit attributable to shareholders decreased by 64.66% to CNY 13,385,086.97 from CNY 37,878,424.18 in 2018[19]. - The company plans to distribute a cash dividend of CNY 0.30 per share, totaling CNY 11,198,108.55, which accounts for 43.23% of the net profit attributable to shareholders[4]. - The basic earnings per share for 2019 was CNY 0.0727, down 32.43% from CNY 0.1076 in 2018[20]. - The weighted average return on equity decreased to 1.49% in 2019 from 2.39% in 2018, a decline of 0.90 percentage points[20]. - The net cash flow from operating activities increased significantly by 281.94% to CNY 111,445,504.03 from CNY 29,179,013.67 in 2018[19]. - Total assets at the end of 2019 were CNY 1,979,851,640.25, a slight increase of 0.25% from CNY 1,974,834,851.60 in 2018[19]. - The company reported a net asset attributable to shareholders of CNY 1,714,985,578.65, a decrease of 3.18% from CNY 1,771,236,818.70 in 2018[19]. Revenue and Sales - The company achieved operating revenue of 754.54 million yuan, a year-on-year increase of 1.26%, with the pharmaceutical industry generating sales revenue of 634.71 million yuan, up 8.44% year-on-year[35]. - The company reported a total annual revenue of CNY 754.54 million for 2019, with Q4 being the lowest quarter due to increased non-recurring expenses[24]. - The company's total revenue for Q1 2019 was CNY 149.88 million, increasing to CNY 209.37 million in Q4 2019, representing a growth of approximately 39.7% over the year[24]. - The pharmaceutical industry reported a total profit of 262.81 billion yuan, with a year-on-year growth of 10.8%, although the growth rate was the lowest in three years[34]. Product Performance - The main product, Jintian Ge Capsule, has established itself as a first-line drug in orthopedic clinical use, contributing to the company's competitive advantage[29]. - The company’s main product, Jintian Ge capsules, holds a market share of 43.92% in the osteoporosis category among traditional Chinese medicine in major public hospitals as of 2019, ranking first[84]. - The sales volume of the second major product, Transfer Factor capsules, was 424,000 boxes, with a revenue of approximately 2.45 million RMB[88]. - Orthopedic product revenue reached ¥521.37 million, an increase of 8.36% year-over-year, with a gross margin of 89.04%[50]. - Immunology product revenue was ¥51.24 million, up 12.99% year-over-year, with a gross margin of 59.99%[50]. - Pediatric product revenue totaled ¥16.99 million, reflecting a 7.56% increase year-over-year, with a gross margin of 61.73%[50]. Research and Development - Research and development expenses surged to 18.17 million yuan, reflecting a 1,972.06% increase compared to the previous year[47]. - The company has 95 R&D personnel, making up 12.34% of the total workforce, reflecting its commitment to research and development[64]. - The company is focusing on four main R&D areas: further development of existing core products, series product development, new traditional Chinese medicine research, and health product development[90]. - The company plans to strengthen collaborations with external R&D institutions to enhance its research capabilities and product offerings[94]. Market Strategy - The company plans to expand its market presence in the northwest regions of China, focusing on pharmaceutical wholesale and retail operations[30]. - The marketing strategy focuses on academic promotion, with the establishment of a nationwide marketing network and collaboration with academic leaders to enhance product application[37]. - The company is actively responding to changes in the industry competitive landscape and government policies to optimize its product and market resources[41]. Risks and Challenges - The company has acknowledged potential risks in its future development strategies, urging investors to be cautious[6]. - The company is facing risks related to industry policy changes, cost pressures, and new product development challenges[117]. - The company is addressing risks associated with fund occupation by its controlling shareholder, ensuring compliance and protecting investor rights[119]. Corporate Governance and Social Responsibility - The company prioritizes investor interests by ensuring transparency and protecting shareholders' rights, following legal regulations and enhancing corporate governance[169]. - The company actively participated in poverty alleviation efforts, donating 30,000 RMB to support infrastructure construction in Xinzhang Village, Shaanxi Province[163]. - The company emphasizes employee welfare, providing health check-ups and professional training to enhance employee skills and career development[168]. - The company has established a volunteer team to engage in various charitable activities, demonstrating its commitment to social responsibility[169]. Environmental Management - The company adheres to environmental regulations, continuously improving its environmental management system to reduce waste emissions and achieve sustainable development[168]. - The company reported no significant environmental issues during the reporting period and did not receive any penalties from environmental protection authorities[171]. - The company’s wastewater treatment facility has a processing capacity of 10 m3/h (240 m3/d) and utilizes an anaerobic + aerobic combined treatment method[171]. - The company has established a comprehensive environmental monitoring program, regularly assessing wastewater, air quality, and noise levels to ensure compliance with environmental standards[173]. Shareholder Information - The total number of ordinary shares remained unchanged during the reporting period, with no significant changes in the shareholding structure[175]. - The largest shareholder, Jinhua Investment Holdings Group Co., Ltd., holds 30.78% of the shares, with 66,897,654 shares pledged[178]. - The company has a total of 66,897,654 shares with limited sale conditions that will become tradable on March 28, 2021[181]. - The total remuneration for all directors, supervisors, and senior management during the reporting period amounted to 2.8244 million yuan[194]. Financial Management - The company has entrusted cash asset management with a total of RMB 19,522.12 million from self-owned funds and RMB 8,500 million from raised funds[143]. - The company has multiple structured deposit agreements with Ping An Bank, with amounts ranging from RMB 1,500 million to RMB 3,000 million, yielding annualized returns between 0.71% and 50.52%[145]. - The company reported a non-operating fund occupation of 345,770,000 RMB, with 178,050,000 RMB cleared during the reporting period[129].

2020 年第一季度报告 公司代码：600080 公司简称：金花股份 金花企业（集团）股份有限公司 2020 年第一季度报告 1 / 22 | 一、 | 重要提示 3 | | --- | --- | | 二、 | 公司基本情况 3 | | 三、 | 重要事项 5 | | 四、 | 附录 7 | 2020 年第一季度报告 √适用 □不适用 一、 重要提示 二、 公司基本情况 2.1 主要财务数据 | | 单位：元 币种：人民币 | | | --- | --- | --- | | 项目 | 本期金额 | 说明 | | 非流动资产处置损益 | -8,059.48 | | | 计入当期损益的政府补助，但与公司正常经营业务密切相关，符合 | 535,691.00 | | | 国家政策规定、按照一定标准定额或定量持续享受的政府补助除外 | | | | 计入当期损益的对非金融企业收取的资金占用费 | | | 3 / 22 单位：元 币种：人民币 本报告期末 上年度末 本报告期末比上 年度末增减(%) 总资产 1,932,214,844.11 1,979,851,640.25 -2.41 归属于上市公司股东的净资产 1,71 ...

Financial Performance - Net profit attributable to shareholders increased by 18.96% to CNY 41,470,353.70 year-to-date[6] - Operating revenue decreased slightly by 0.31% to CNY 545,170,006.93 compared to the same period last year[6] - Basic earnings per share increased by 11.77% to CNY 0.1111[7] - The company reported a net profit of CNY 5,438,877.39 for Q3 2019, up from CNY 3,741,514.62 in Q3 2018, marking an increase of approximately 45.4%[25] - The total profit for Q3 2019 was ¥20,274,479.42, compared to ¥18,510,182.61 in the same period last year, indicating a year-over-year increase of about 9.5%[26] - The net profit for the first three quarters of 2019 was ¥38,713,986.67, up 10.4% from ¥35,159,981.88 in the same period of 2018[30] Cash Flow - The net cash flow from operating activities was CNY 79,716,690.78, a significant improvement from a negative cash flow of CNY 15,847,438.95 in the previous year[6] - Net cash flow from operating activities improved to ¥79,716,690.78 compared to a negative cash flow of ¥15,847,438.95 in the previous period[14] - Net cash flow from investment activities was positive at ¥23,300,754.65, a substantial recovery from a negative cash flow of ¥386,988,382.45[14] - Cash inflow from operating activities for Q3 2019 was CNY 510,505,300.90, an increase from CNY 459,763,963.66 in Q3 2018, representing an increase of approximately 11.0%[36] - The net cash flow from financing activities for Q3 2019 was negative CNY 17,498,394.71, compared to a positive cash flow of CNY 562,266,764.82 in Q3 2018[33] Assets and Liabilities - Total assets increased by 2.97% to CNY 2,033,467,003.32 compared to the end of the previous year[6] - The company's total liabilities increased to ¥234,685,316.26 from ¥203,364,479.66 in the previous year[20] - Cash and cash equivalents increased to ¥442,319,903.67 from ¥356,800,852.95 year-over-year[18] - Total assets as of Q3 2019 amounted to CNY 1,984,285,909.00, up from CNY 1,925,430,703.54 in Q2 2019, indicating growth in the asset base[23] - Current liabilities reached CNY 198,193,320.13, while total liabilities were CNY 203,364,479.66[40] Shareholder Information - The company had a total of 32,432 shareholders at the end of the reporting period[9] - The largest shareholder, Jinhua Investment Holding Group, holds 30.78% of the shares[9] Research and Development - R&D expenses increased significantly to ¥9,621,376.61 from ¥609,795.56, representing a growth of 1477.80%[14] - Research and development expenses for Q3 2019 were CNY 7,933,702.78, significantly higher than CNY 204,454.30 in Q3 2018, reflecting a substantial increase in investment in innovation[25] - Research and development expenses surged to ¥9,621,376.61 in the first three quarters of 2019, a significant increase from ¥609,795.56 in the same period of 2018, reflecting a focus on innovation[29] Financial Management - Financial expenses decreased to -¥4,185,549.67 due to increased interest income and reduced bank loan interest expenses[14] - The company reported a financial income of ¥4,396,398.66 in Q3 2019, compared to ¥2,278,032.41 in Q3 2018, indicating improved financial management[29] Future Outlook - Future outlook includes continued focus on operational efficiency and potential market expansion strategies, although specific figures were not disclosed[28] - The company is actively pursuing new product development and technological advancements to enhance market competitiveness, though detailed metrics were not provided[28] - The company plans to continue expanding its market presence and investing in new technologies to drive future growth[30]

Financial Performance - The company's operating revenue for the first half of 2019 was CNY 346,125,198.01, a decrease of 2.11% compared to CNY 353,585,221.08 in the same period last year[19]. - The net profit attributable to shareholders of the listed company was CNY 24,863,415.69, an increase of 23.74% from CNY 20,093,525.91 in the previous year[19]. - The net cash flow from operating activities was CNY 11,524,390.87, a significant improvement from a negative cash flow of CNY -16,878,541.49 in the same period last year[19]. - The total assets at the end of the reporting period were CNY 1,975,237,319.16, a slight increase of 0.02% from CNY 1,974,834,851.60 at the end of the previous year[19]. - The net assets attributable to shareholders of the listed company increased by 0.58% to CNY 1,781,524,537.75 from CNY 1,771,236,818.70 at the end of the previous year[19]. - Basic earnings per share for the first half of 2019 were CNY 0.0666, up 12.50% from CNY 0.0592 in the same period last year[20]. - The company achieved operating revenue of CNY 346.13 million, a decrease of 2.11% compared to the same period last year[40]. - The pharmaceutical industry segment reported sales revenue of CNY 289.45 million, an increase of 8.01% year-on-year[40]. - The net profit attributable to shareholders was CNY 24.86 million, representing a growth of 23.74% compared to the previous year[40]. - The total profit for the first half of 2019 was CNY 22,868,920.33, slightly down from CNY 24,097,183.74 in the same period of 2018[99]. - The company reported a total comprehensive income of CNY 20,330,327.37 for the period[118]. Business Operations - The company’s main business includes the research, production, and sales of pharmaceuticals, covering over 100 varieties and specifications[24]. - The leading product, Jintian Ge Capsule, is a national class I new drug and has become a first-line medication in orthopedic clinical use[24]. - The company operates its pharmaceutical wholesale and retail business primarily in the northwest regions of China, including Shaanxi, Gansu, and Qinghai[24]. - The company has established a nationwide marketing network, focusing on academic promotion and collaboration with authoritative organizations to enhance product application and development[32]. - The company plans to enhance its market coverage through a series of academic promotional activities and compliance transformation strategies[36]. - The company is focusing on optimizing core commercial channels and expanding its customer base to drive sales growth[38]. - The company has increased its R&D investment to develop related research and a series of products in the orthopedic field, enhancing its core competitiveness[31]. Industry Overview - The pharmaceutical industry in China achieved a total revenue of CNY 12,227.5 billion in the first half of 2019, representing a year-on-year growth of 8.5%[28]. - The production of chemical raw drugs reached 1.684 million tons, a decrease of 1.3%, while traditional Chinese medicine production increased by 10.9% to 1.481 million tons[28]. - The gross profit margin for the pharmaceutical industry was reported at 42.9%, with a net profit margin of 13.2%[28]. - The average per capita healthcare expenditure in China reached CNY 941, reflecting a year-on-year increase of 9.5%[28]. Financial Management - The company does not plan to distribute profits or increase capital from reserves during the reporting period[6]. - The company faced industry policy risks due to changes in drug procurement and pricing regulations, which could impact future operations[49]. - The company reported a significant increase in accounts receivable by 88.54% to CNY 21.51 million, indicating potential liquidity concerns[44]. - The company has pledged assets worth CNY 50 million as collateral for a bank loan, indicating financial leverage[46]. - The company has implemented measures to enhance cost control awareness across all levels of operation[51]. - The company has not proposed any profit distribution or capital reserve transfer plans for the half-year period[54]. - The company continues to employ Ruihua Certified Public Accountants for its financial and internal control audits for 2019[56]. - The company has not reported any changes in accounting policies or significant accounting errors during the reporting period[72]. Environmental Responsibility - The company has implemented a low-nitrogen transformation for its natural gas boiler, achieving nitrogen oxide emissions concentration of 26.67 mg/m³, which complies with the local environmental standards of below 30 mg/m³[69]. - During the reporting period, the company processed approximately 0.91 tons of wastewater with a CODcr concentration of 36 mg/L, and all pollutants met the discharge standards[68]. - The company has a wastewater treatment capacity of 10 m³/h (240 m³/d) and utilizes an anaerobic + aerobic combined process for treatment[67]. - The company generated approximately 11.3 tons of hazardous waste in the first half of 2019, which is regularly disposed of by a certified waste management company[69]. - The company has established an emergency response plan for environmental incidents, which has been reviewed and filed with the local environmental authority[70]. - The company has not faced any significant environmental issues or penalties during the reporting period[67]. - The company’s environmental monitoring includes regular assessments of wastewater, waste gas, and noise, all of which have met the required standards[69]. - The company has maintained its environmental protection facilities, ensuring they are well-maintained and operational[67]. Corporate Governance - The company experienced a change in its board of directors, with Qin Chuan resigning and Han Zhuojun being elected as a new director[82]. - The company has not undergone any changes in its controlling shareholders or actual controllers during the reporting period[80]. - There were no significant changes in the shareholding of directors, supervisors, and senior management during the reporting period[81]. - The company has not issued any preferred shares during the reporting period[84]. - The company has no major litigation or arbitration matters during the reporting period, indicating a stable legal environment[57]. - The company has no significant related party transactions or major contracts that require disclosure during the reporting period[59]. Research and Development - Research and development expenses increased by 300.49% to CNY 1.69 million, reflecting a significant investment in innovation[43]. - The company plans to accelerate the progress of existing R&D projects and increase investment in new product development, focusing on policy, technical feasibility, market prospects, and investment amounts[51]. - Research and development expenses increased to CNY 1,687,673.83, up from CNY 421,400.73, highlighting a focus on innovation[95]. - The company recognizes intangible assets from R&D projects upon obtaining necessary regulatory approvals, such as new drug certificates[181]. Accounting Policies - The company adheres to the accounting standards set by the Ministry of Finance, ensuring the financial statements reflect a true and complete picture of its financial status[124]. - The company’s accounting period runs from January 1 to December 31 each year[125]. - The company’s accounting currency is Renminbi (CNY)[127]. - The company recognizes expected losses on loss contracts as provisions when the costs exceed the expected economic benefits[189]. - The company measures provisions for restructuring obligations based on direct costs associated with detailed and publicly announced plans[189]. - The company classifies perpetual bonds and preferred stocks as equity instruments if they meet specific criteria, including not requiring cash or other financial assets delivery under adverse conditions[194]. - Revenue from product sales is recognized when the significant risks and rewards of ownership have been transferred to the buyer, and the amount can be reliably measured[196].

Financial Performance - Net profit attributable to shareholders was CNY 11,066,913.57, an increase of 74.41% year-on-year[6]. - Operating revenue for the period was CNY 149,881,020.33, down 4.63% from the same period last year[6]. - The net cash flow from operating activities was CNY 4,626,722.76, a significant improvement from a negative CNY 10,137,822.51 in the previous year[6]. - Basic earnings per share rose by 42.31% to CNY 0.0296[6]. - Total operating revenue for Q1 2019 was ¥149,881,020.33, a decrease of 4.1% from ¥157,156,466.36 in Q1 2018[25]. - Net profit for Q1 2019 reached ¥11,249,485.18, an increase of 92.5% compared to ¥5,848,476.27 in Q1 2018[25]. - Operating profit for Q1 2019 was ¥12,373,436.25, up 76.5% from ¥7,020,640.47 in Q1 2018[25]. - Earnings per share for Q1 2019 was ¥0.0296, compared to ¥0.0208 in Q1 2018, reflecting a 42.3% increase[26]. - Net profit for Q1 2019 reached CNY 8.30 million, up 33.69% from CNY 6.20 million in Q1 2018[28]. - Operating profit for Q1 2019 was CNY 9.04 million, an increase of 22.73% compared to CNY 7.36 million in Q1 2018[28]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 1,969,060,141.16, a decrease of 0.29% compared to the end of the previous year[6]. - Current assets totaled CNY 893,760,502.56, down from CNY 899,195,829.09 at the end of 2018, reflecting a decrease of approximately 0.5%[16]. - Total liabilities decreased to CNY 186,163,707.54 from CNY 203,364,479.66, a reduction of about 8.5%[18]. - Total liabilities as of Q1 2019 were ¥137,874,801.65, a decrease of 10.3% from ¥153,752,765.93 in Q1 2018[25]. - The company reported a total liability of 203,364,479.66 RMB, with current liabilities amounting to 198,193,320.13 RMB, indicating a stable short-term financial position[35]. - Total assets amounted to $1,925,430,703.54 as of the end of Q1 2019[38]. - Current assets totaled $833,559,554.87, with cash and cash equivalents at $351,951,120.44[37]. - Non-current assets reached $1,091,871,148.67, including long-term equity investments of $716,666,476.79[38]. Shareholder Information - The number of shareholders at the end of the reporting period was 41,645[9]. - Shareholders' equity increased to CNY 1,782,896,433.62 from CNY 1,771,470,371.94, reflecting a growth of approximately 0.7%[18]. - Total equity for Q1 2019 was ¥1,780,152,485.52, an increase from ¥1,771,677,937.61 in Q1 2018[25]. - The company’s total equity amounted to 1,771,470,371.94 RMB, reflecting a stable capital structure[35]. Cash Flow - Cash flow from operating activities generated a net amount of CNY 4.63 million, a significant improvement from a net outflow of CNY 10.14 million in Q1 2018[30]. - Total cash inflow from investment activities was CNY 410.20 million, compared to CNY 3.00 million in Q1 2018[30]. - Cash flow from financing activities resulted in a net outflow of CNY 0.76 million, down from a net inflow of CNY 627.84 million in Q1 2018[30]. - The ending balance of cash and cash equivalents was CNY 452.39 million, a decrease from CNY 660.15 million at the end of Q1 2018[30]. - The net increase in cash and cash equivalents for Q1 2019 was 26,698,580.87 RMB, a sharp decline from 622,401,110.14 RMB in Q1 2018, indicating reduced liquidity[32]. Investment and Income - The company reported a 33.42% increase in trading financial assets, reaching CNY 2,371,600.00[12]. - Investment income surged by 114.05% to CNY 4,993,613.18, attributed to increased earnings from joint ventures[12]. - The company reported investment income of ¥4,993,613.18 in Q1 2019, significantly higher than ¥2,332,940.14 in Q1 2018[25]. - The company reported an increase in investment income to CNY 4.99 million, up from CNY 2.33 million in Q1 2018[28]. Expenses - Research and development expenses for Q1 2019 were ¥272,485.29, up 42.7% from ¥190,892.83 in Q1 2018[25]. - Sales expenses rose to CNY 76.10 million, compared to CNY 73.79 million in the same period last year, reflecting a 4.22% increase[28]. - Tax expenses for Q1 2019 were ¥1,527,568.45, slightly down from ¥1,620,868.26 in Q1 2018[25]. Financial Position - The total liabilities to equity ratio improved, indicating a stronger financial position compared to the previous period[18]. - The company implemented new financial instrument standards, which resulted in reclassification of certain financial assets, impacting the financial statements[36]. - The company reclassified financial assets under new accounting standards effective January 1, 2019, impacting the classification of certain financial instruments[39].

Financial Performance - In 2018, the company's operating revenue was CNY 745,161,287.68, a decrease of 1.59% compared to CNY 757,182,461.12 in 2017[20] - The net profit attributable to shareholders was CNY 38,322,012.62, down 28.32% from CNY 53,462,801.12 in the previous year[20] - The basic earnings per share decreased to CNY 0.1076, a decline of 28.31% from CNY 0.1501 in 2017[21] - The total assets at the end of 2018 reached CNY 1,974,834,851.60, representing a 39.16% increase from CNY 1,419,114,899.93 in 2017[20] - The weighted average return on equity decreased to 2.39%, down 2.49 percentage points from 4.88% in 2017[21] - The net cash flow from operating activities was CNY 29,179,013.67, a decrease of 31.93% compared to CNY 42,865,568.51 in 2017[20] - The company achieved operating revenue of 74,516.13 million yuan, a decrease of 1.59% year-on-year, while the pharmaceutical industry segment reported sales revenue of 58,530.26 million yuan, an increase of 4.71%[40] - The net profit attributable to shareholders was 3,832.20 million yuan, a decrease of 28.32% year-on-year, while the net profit after deducting non-recurring gains and losses increased by 12.33% to 3,787.84 million yuan[40] Shareholder Returns - The company proposed a cash dividend of CNY 0.40 per share, totaling CNY 14,930,811.40, which accounts for 38.96% of the net profit attributable to shareholders[5] - In 2017, the company distributed cash dividends amounting to 11.2 million yuan, representing 20.95% of the net profit attributable to shareholders[126] - The cash dividend for 2018 is set at 0.40 yuan per 10 shares, with a total distribution of approximately 14.9 million yuan, accounting for 38.96% of the net profit attributable to shareholders[128] Capital Management - The company completed a non-public offering of 67,974,413 shares in March 2018, increasing the total share capital to 373,270,285 shares[22] - The company completed a non-public stock issuance to enhance capital strength and support the expansion of the orthopedic industry chain[54] - The company completed a private placement, significantly boosting its capital reserve to 811,978,888.08 RMB, an increase of 221.45%[79] - The company has pledged assets worth 50 million RMB as collateral for a bank loan, indicating a strategic move to secure funding[81] Market and Business Strategy - The company plans to continue expanding its market presence in the northwest regions of China, focusing on both wholesale and retail pharmaceutical operations[32] - The company has established a nationwide marketing network through a招商代理模式, focusing on academic promotion and building an expert network[35] - The company aims to enhance its marketing strategy by increasing academic promotion efforts, improving professionalism, precision, and systematic approaches to extend the brand's influence[119] - The company is focusing on the development of hospital distribution business as part of its strategic shift in the pharmaceutical commercial segment[112] Research and Development - The company has increased R&D investment, focusing on the development of core products in the orthopedic field to enhance its competitive advantage[43] - The company’s R&D expenses increased by 19.33% to 876,932.08 RMB, reflecting a commitment to innovation[58] - The company is focusing on three main R&D areas: further development of core products, development of series products, and new traditional Chinese medicine[97] - The company has established collaborations with external R&D institutions to enhance its R&D capabilities and product line[97] Environmental and Social Responsibility - The company has implemented environmental protection measures, ensuring that wastewater discharge meets the required standards, with a CODcr average concentration of 87 mg/L and a total discharge of approximately 2.88 tons[155] - The company actively participated in poverty alleviation projects in Shaanxi Province, focusing on infrastructure construction, agricultural development, housing renovation, and medical assistance[146] - The company allocated 5 million RMB for poverty alleviation efforts, including infrastructure and medical support for impoverished households[150] Employee Management and Training - The total number of employees in the parent company and major subsidiaries is 770, with 479 in the parent company and 291 in subsidiaries[188] - The company has established a training points system for different job levels, with specific points assigned for passing assessments[194] - The training plan for 2018 aims to enhance the skills of middle and grassroots management personnel, improve technical theory levels, and increase operational skills[190] - The company emphasizes the importance of training evaluation, linking employee training points to annual performance assessments, with a threshold for passing set at 70%[199] Risk Management - The company has outlined potential risks in its future development strategies, which are detailed in the report[7] - The company faces industry policy risks due to ongoing medical reforms and regulatory changes, which could significantly impact future development[122] - Rising raw material prices and increasing labor costs pose significant pressure on the company's profit margins and overall cost structure[122] - The company has implemented measures to monitor industry policy changes and optimize operational management to mitigate potential risks[123]

2018 年第三季度报告 | 目录 | | --- | | 一、 | 重要提示 | 3 | | --- | --- | --- | | 二、 | 公司基本情况 | 3 | | 三、 | 重要事项 | 5 | | 四、 | 附录 | 8 | 2018 年第三季度报告 一、 重要提示 1.1 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和连带的法律责任。 1.2 公司全体董事出席董事会审议季度报告。 1.3 公司负责人吴一坚、主管会计工作负责人侯亦文及会计机构负责人（会计主管人员）李琴保 证季度报告中财务报表的真实、准确、完整。 公司代码：600080 公司简称：金花股份 金花企业（集团）股份有限公司 2018 年第三季度报告 1 / 19 2018 年第三季度报告 | | | 非经常性损益项目和金额 √适用 □不适用 1.4 本公司第三季度报告未经审计。 二、 公司基本情况 2.1 主要财务数据 单位：元 币种：人民币 | | 本报告期末 | | 上年度末 | | 本报告期末比上年 | | | | --- | --- | - ...

Financial Performance - The company's operating revenue for the first half of 2018 was CNY 353,585,221.08, a decrease of 2.01% compared to the same period last year[19]. - The net profit attributable to shareholders increased by 44.51% year-on-year, reaching CNY 20,093,525.91[19]. - Basic earnings per share rose by 30.11% to CNY 0.0592 compared to the same period last year[20]. - The company achieved operating revenue of CNY 353.59 million, a decrease of 2.01% compared to the same period last year[42]. - The net profit attributable to shareholders was CNY 20.09 million, an increase of 44.51% compared to the previous year[42]. - The company reported a significant increase in other receivables, up 197.60% to CNY 41.87 million, primarily due to guarantee payments made by a subsidiary[46]. - The hotel business revenue increased by 21.77% to CNY 22.16 million, contributing to reduced losses compared to the previous year[42]. - The company reported a profit distribution of CNY -11,198,108.55 to shareholders, indicating a reduction in profit allocation compared to previous distributions[108]. Assets and Liabilities - Total assets increased by 44.86% from the previous year-end, amounting to CNY 2,055,762,023.27[21]. - The company's cash and cash equivalents increased significantly to CNY 640.29 million, representing 31.15% of total assets[46]. - Total liabilities amounted to CNY 302,101,405.36, slightly up from CNY 300,688,608.61, indicating a marginal increase of 0.5%[87]. - Owner's equity reached CNY 1,753,660,617.91, up from CNY 1,118,426,291.32, representing a growth of approximately 56.7%[87]. - The total equity of the company rose to CNY 1,752,025,382.15, compared to CNY 1,115,899,478.03, marking an increase of 57%[91]. - The total owner's equity at the end of the reporting period was CNY 1,753,660,617.91, up from CNY 1,318,977.35 in the previous period, reflecting an increase of approximately 32.94%[106]. Cash Flow - The company’s cash flow from operating activities was negative at CNY -16,878,541.49, contrasting with a positive cash flow of CNY 7,636,076.10 in the same period last year[19]. - Cash inflow from operating activities totaled 369,248,432.40 RMB, down from 386,969,419.41 RMB in the prior period, reflecting a decrease of approximately 4.4%[98]. - The net cash flow from investment activities was 866,293.92 RMB, a significant improvement from -18,749,734.21 RMB in the previous period[99]. - The net cash flow from financing activities was 614,390,937.16 RMB, a substantial increase compared to -3,782,083.35 RMB in the previous period[99]. Business Operations - The company’s main business includes the research, production, and sales of pharmaceuticals, with a product line covering over 100 varieties[24]. - The leading product, Jintian Ge Capsule, is recognized as a first-class new drug in the orthopedic clinical field[24]. - The pharmaceutical wholesale and retail business is primarily operated by Shaanxi Jinhua Pharmaceutical Co., focusing on the northwest regions of China[24]. - The company has established a nationwide marketing network, focusing on academic promotion and collaboration with authoritative organizations to enhance product application[33]. - The company has a core competitive advantage in the orthopedic field, supported by significant R&D investments and product development[32]. Market and Industry - The pharmaceutical industry in China saw a main business income of 1,033.48 billion RMB in the first five months of 2018, representing a year-on-year growth of 13.9%[28]. - The pharmaceutical industry experienced a profit total of 123.17 billion RMB in the same period, with a year-on-year increase of 13.2%[28]. - The company is facing industry policy risks due to ongoing reforms in the national medical system, which may impact market competition[49]. Shareholder and Equity Management - The company completed a non-public offering of 67,974,413 shares at a price of 9.38 RMB per share, raising a total of approximately 637.6 million RMB, with a net amount of about 628.8 million RMB after expenses[30]. - The company has committed to a share repurchase plan with a total amount not exceeding 2 million yuan, aimed at supporting employee stock ownership plans[55]. - The company completed the first phase of its employee stock ownership plan, acquiring 1,076,759 shares through a private placement[58]. - The largest shareholder, Jinhua Investment Holdings Group Co., Ltd., holds 114,897,654 shares, representing 30.78% of the total shares, with 66,897,654 shares pledged[77]. Compliance and Governance - The company has no major litigation or arbitration matters during the reporting period, indicating a stable legal environment[56]. - The company has retained Ruihua Certified Public Accountants for its 2018 financial and internal control audits, ensuring ongoing oversight and compliance[56]. - The company continues to engage with its stakeholders and ensure compliance with commitments made regarding shareholding and stock issuance[54]. Environmental and Social Responsibility - The company actively participated in poverty alleviation efforts, focusing on infrastructure construction, stable development of planting industries, housing renovation for impoverished households, and medical assistance[63]. - The company emphasized its commitment to environmental protection, stating it is not classified as a key pollutant unit and has not faced significant penalties for environmental issues during the reporting period[70]. - The company has implemented measures to promote energy conservation and a green office environment, including advocating for paperless operations and encouraging employees to save electricity and water[70].

2018 年第一季度报告 公司代码：600080 公司简称：金花股份 金花企业（集团）股份有限公司 2018 年第一季度报告 1 / 17 | 一、 | 重要提示 3 | | --- | --- | | 二、 | 公司基本情况 3 | | 三、 | 重要事项 5 | | 四、 | 附录 7 | 2018 年第一季度报告 一、 重要提示 二、 公司基本情况 2.1 主要财务数据 单位：元 币种：人民币 单位：元 币种：人民币 | 项目 | 本期金额 | 说明 | | --- | --- | --- | | 非流动资产处置损益 | -49,211.17 | | | 计入当期损益的政府补助，但与公司正常经营业务密切相关，符合国 | 500,000.00 | | 3 / 17 1.1 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整，不 存在虚假记载、误导性陈述或者重大遗漏，并承担个别和连带的法律责任。 1.2 公司全体董事出席董事会审议季度报告。 1.3 公司负责人吴一坚、主管会计工作负责人侯亦文及会计机构负责人（会计主管人员）李琴保证 季度报告中财务报表的真实、准确、完整。 1.4 ...

Financial Performance - In 2017, the company's operating revenue reached ¥757,182,461.12, representing a year-on-year increase of 13.58% compared to ¥666,645,492.79 in 2016[22] - The net profit attributable to shareholders of the listed company was ¥53,462,801.12, a significant increase of 95.84% from ¥27,299,103.90 in the previous year[22] - The basic earnings per share for 2017 was ¥0.1751, up 95.86% from ¥0.0894 in 2016[23] - The total assets of the company at the end of 2017 were ¥1,419,114,899.93, a decrease of 1.72% from ¥1,443,952,623.62 at the end of 2016[22] - The net cash flow from operating activities was ¥42,865,568.51, reflecting a slight increase of 2.85% from ¥41,676,486.75 in 2016[22] - The company’s net assets attributable to shareholders increased to ¥1,116,758,228.46, up 4.13% from ¥1,072,454,303.50 in 2016[22] - The weighted average return on net assets was 4.88%, an increase of 2.30 percentage points from 2.58% in 2016[23] Revenue and Profit Analysis - The company's total revenue for the reporting period was RMB 75,718.25 million, with quarterly revenues of RMB 17,008.32 million, RMB 19,074.07 million, RMB 18,845.28 million, and RMB 20,790.57 million respectively[26] - The net profit attributable to the parent company for the reporting period was RMB 5,346.28 million, with significant quarterly fluctuations: RMB 591.86 million, RMB 798.59 million, RMB 1,494.13 million, and RMB 2,461.70 million[26] - Non-recurring gains and losses for the reporting period totaled RMB 1,974.16 million, primarily due to a high non-recurring gain in the fourth quarter from performance compensation and write-off matters[26] - The adjusted operating profit after tax for the reporting period was RMB 3,156.89 million, with an adjusted operating profit margin of 4.17%[26] Market and Industry Overview - The pharmaceutical industry in China saw a sales revenue of RMB 29,463 billion in 2016, with a year-on-year growth of 10.3%[37] - The total profit of the Chinese pharmaceutical industry reached RMB 320.1 billion in 2016, reflecting a year-on-year increase of 16.4%[38] - The pharmaceutical distribution market in China achieved a sales scale of CNY 1,399.4 billion in 2016, with a year-on-year growth of 11.6%[41] - The compound annual growth rate (CAGR) of China's pharmaceutical terminal market sales from 2012 to 2016 was 11.9%, although the growth rate in 2016 was 8.3%, down by 2.7 percentage points year-on-year[43] Research and Development - The company is focusing on product research and development, collaborating with external research institutions to enhance its core products and develop new series[57] - The company plans to enhance its R&D capabilities and product offerings to support future growth and market expansion[103] - The company's R&D investment for the reporting period amounted to RMB 17.05 million, accounting for 2.25% of the operating revenue, which is comparable to the industry average[106] - The company has invested RMB 1,987.31 million in the ongoing research of Jintian Ge Capsule, which is currently in the clinical research phase[108] Sales and Marketing Strategy - The company’s sales model includes a nationwide marketing network, emphasizing academic promotion and strategic brand building[35] - The company plans to enhance its product marketing through academic promotion and has integrated its main product into several clinical guidelines, boosting its academic standing in the orthopedic field[54] - The company intends to strengthen its market position in the orthopedic field through product innovation and strategic acquisitions[124] Financial Management and Investments - The company has completed a non-public stock issuance to increase its capital strength and expand its business scale, supporting the integration of the orthopedic industry chain[59] - The company engaged in bank entrusted wealth management with a total amount of CNY 29 million, with an outstanding balance of CNY 26.09 million[151] - The total investment in non-principal guaranteed financial products by China Construction Bank amounted to 450 million, with a return of 0.23%[153] Corporate Governance and Shareholder Structure - The company has established a comprehensive corporate governance structure in compliance with the Company Law and relevant regulations, ensuring clear responsibilities among its governing bodies[194] - The total number of ordinary shareholders at the end of the reporting period was 24,205, an increase from 24,010 at the end of the previous month[168] - The largest shareholder, Jinhua Investment Holding Group, holds 48,000,000 shares, representing 15.72% of total shares, with all shares pledged[170] Social Responsibility - The company actively participated in poverty alleviation efforts, helping 2 registered impoverished households to escape poverty[160] - The company has committed to ongoing social responsibility initiatives, including infrastructure development and vocational training for impoverished populations[161] Employee Management and Training - The company has implemented a training plan aimed at enhancing the skills and competencies of management and employees to meet rapid development needs[191] - The company has a policy of 100% coverage for employee training, ensuring all employees participate in the training programs[192] Risk Management - The company faces significant risks from industry policy changes, rising raw material costs, and price reductions in drug procurement, which could pressure profit margins[128] - The company has implemented measures to enhance market analysis and adjust strategies in response to policy changes, while also focusing on cost control through technological improvements and energy savings[129]